Restricted accessResearch articleFirst published online 2001-8
Global Strategy for the Diagnosis,Management,and Prevention of Chronic Obstructive Pulmonary Disease: National Heart,Lung,and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive Summary
Chronic obstructive pulmonary disease is a major cause of chronic morbidity and mortality throughout the world. COPD is currently the fourth leading cause of death in the world, and further increases in the prevalence and mortality of the disease can be predicted in the coming decades. A unified international effort is required to reverse these trends. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a collaborative project of the United States NHLBI and WHO. Its goals are to increase awareness of COPD and decrease morbidity and mortality from this disease. GOLD aims to improve prevention and management of COPD through a concerted worldwide effort of people involved in all facets of health care and health care policy, and to encourage a renewed research interest in this extremely prevalent disease. The GOLD Workshop Report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, presents a COPD management plan with 4 components: (1) assess and monitor disease, (2) reduce risk factors, (3) manage stable COPD, and (4) manage exacerbations. The Workshop Report is based on the best-validated current concepts of COPD pathogenesis and the available evidence on the most appropriate management and prevention strategies. It has been developed by individuals with expertise in COPD research and patient care and extensively reviewed by many experts and scientific societies. Before its release for publication, the Workshop Report was reviewed by the NHLBI and the WHO. This Executive Summary provides key information about COPD; the full Workshop Report provides more details.
National Heart, Lung, and Blood Institute. Morbidity & Mortality. Chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998. Available from: http://www.nhlbi.nih.gov/nhlbi/seiin//other/cht-book/htm.
2.
MurrayCJL, LopezAD. Evidence-based health policy lessons from the global burden of disease study. Science1996;274:740–743.
HillAT, BayleyD, StockleyRA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med1999;160:893–898.
5.
KeatingsVM, CollinsPD, ScottDM, BarnesPJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med1996;153:530–534.
6.
PesciA, BalbiB, MajoriM, CaccianiG, BertaccoS, AlciatoP, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J1998;12:380–386.
7.
YamamotoC, YonedaT, YoshikawaM, FuA, TokuyamaT, TsukaguchiK, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest1997;112:505–510.
8.
MuellerR, ChanezP, CampbellAM, BousquetJ, HeusserC, BullockGR. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med1996;90:79–85.
9.
MullenJB, WrightJL, WiggsBR, ParePD, HoggJC. Reassessment of inflammation of airways in chronic bronchitis. BMJ1985;291:1235–1239.
10.
CosioM, GhezzoH, HoggJC, CorbinR, LovelandM, DosmanJ, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med1978;298:1277–1281.
11.
NiewoehnerDE, KleinermanJ, RiceDB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med1974;291:755–758.
12.
WrightJL, LawsonLM, ParePD, WiggsBJ, KennedyS, HoggJC. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis1983;127:474–477.
13.
OllerenshawSL, WoolcockAJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis1992;145:922–927.
14.
HunninghakeGW, CrystalRG. Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis1983;128:833–838.
15.
LiXY, BrownD, SmithS, MacNeeW, DonaldsonK.Short-term inflammatory responses following intratracheal instillation of fine and ultrafine carbon black in rats. Inhal Toxicol1999;11:709–731.
16.
MonnC, BeckerS.Cytotoxicity and induction of proinflammatory cytokines from human monocytes exposed to fine (PM2.5) and coarse particles (PM10-2.5) in outdoor and indoor air. Toxicol Appl Pharmacol1999;155:245–252.
17.
SalviS, BlombergA, RudellB, KellyF, SandstromT, HolgateST, et al. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med1999;159:702–709.
18.
Von EssenSG, O'NeillDP, McGranaghanS, OlenchockSA, RennardSI. Neutrophilic respiratory tract inflammation and peripheral blood neutrophilia after grain sorghum dust extract challenge. Chest1995;108:1425–1433.
19.
Von EssenSG, RobbinsRA, ThompsonAB, ErtlRF, LinderJ, RennardSI. Mechanisms of neutrophil recruitment to the lung by grain dust exposure. Am Rev Respir Dis1988;138:921–927. (Erratum appears in Am Rev Respir Dis 1989;139:1065.)
20.
O'ShaughnessyTC, AnsariTW, BarnesNC, JefferyPK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med1997;155:852–857.
21.
SaettaM, Di StefanoA, MaestrelliP, FerraressoA, DrigoR, PotenaA, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis1993;147:301–306.
22.
SaettaM, Di StefanoA, TuratoG, FacchiniFM, CorbinoL, MappCE, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998;157:822–826.
23.
LeopoldJG, GoeffJ.Centrilobular form of hypertrophic emphysema and its relation to chronic bronchitis. Thorax1957;12:219–235.
24.
McLeanKA. Pathogenesis of pulmonary emphysema. Am J Med1958;25:62–74.
25.
RepineJE, BastA, LankhorstI.Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med1997;156:341–357.
26.
WrightJL, LawsonL, ParePD, HooperRO, PeretzDI, NelemsJM, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease: the effect of oxygen and exercise. Am Rev Respir Dis1983;128:702–707.
27.
PeinadoVI, BarberaJA, AbateP, RamirezJ, RocaJ, SantosS, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med1999;159:1605–1611.
MacNeeW.Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part 2. Am J Respir Crit Care Med1994;150:1158–1168.
30.
PrideNB, VermeireP, AllegraL.Diagnostic labels applied to model case histories of chronic airflow obstruction: responses to a questionnaire in 11 North American and Western European countries. Eur Respir J1989;2:702–709.
31.
ManninoDM, BrownC, GiovinoGA. Obstructive lung disease deaths in the United States from 1979 through 1993: an analysis using multiple-cause mortality data. Am J Respir Crit Care Med1997;156:814–818.
32.
MurrayCJL, LopezAD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge MA: Harvard University Press; 1996.
33.
National Health Service Executive. Burden of disease: a discussion document. London: Department of Health; 1996.
34.
Rutten-van MolkenMP, PostmaMJ, JooreMA, Van GenugtenML, LeidlR, JagerJC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med1999;93:779–787.
35.
JacobsonL, HertzmanP, LofdahlC-G, SkooghB-E, LindgrenB.The economic impact of asthma and COPD in Sweden 1980 and 1991. Respir Med2000;94:247–255.
36.
BuistAS, VollmerWM. Smoking and other risk factors. In: MurrayJF, NadelJA, editors. Textbook of respiratory medicine. Philadelphia: WB Saunders; 1994:1259–1287.
37.
ThomTJ. International comparisons in COPD mortality. Am Rev Respir Dis1989;140:S27–S34.
38.
XuX, WeissST, RijckenB, SchoutenJP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J1994;7:1056–1061.
39.
FeinleibM, RosenbergHM, CollinsJG, DelozierJE, PokrasR, ChevarleyFM. Trends in COPD morbidity and mortality in the United States. Am Rev Respir Dis1989;140:S9–S18.
40.
US Centers for Disease Control and Prevention. Vital and health statistics: current estimates from the National Health Interview Survey. Department of Health and Human Services, Public Health Service; 1995. Publication No:96-1527.
41.
AnthonisenNR, ConnettJE, KileyJP, AltoseMD, BaileyWC, BuistAS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272:1497–1505.
42.
LaurellCB, ErikssonS.The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest1963;15:132–140.
43.
HubbardRC, CrystalRG. Antiproteases. In: CrystalRB, WestJB, BarnesPJ, CherniackNS, WeibelER, editors. The lung: scientific foundations. New York: Raven Press; 1991:1775–1787.
44.
McElvaneyNG, CrystalRG. Inherited susceptibility of the lung to proteolytic injury. In: CrystalRG, WestJB, WeibelER, BarnesPJ, editors. The lung: scientific foundations. Philadelphia: Lippincott-Raven; 1997:2537–2553.
45.
OrieNGM, SluiterHJ, De VreisK, TammerlingK, WikopJ.The host factor in bronchitis. In: OrieNGM, SluiterHG, editors. Bronchitis, an international symposium. Assen, Netherlands: Royal Vangorcum; 1961:43–59.
46.
HagstromB, NybergP, NilssonPM. Asthma in adult life is there an association with birth weight? Scand J Prim Health Care1998;16:117–120.
47.
SvanesC, OmenaasE, HeuchJM, IrgensLM, GulsvikA.Birth characteristics and asthma symptoms in young adults: results from a population-based cohort study in Norway. Eur Respir J1998;12:1366–1370.
48.
TodiscoT, de BenedictisFM, IannacciL, BaglioniS, EslamiA, TodiscoE, et al. Mild prematurity and respiratory functions. Eur J Pediatr1993;152:55–58.
49.
SteinCE, KumaranK, FallCH, ShaheenSO, OsmondC, BarkerDJ. Relation of fetal growth to adult lung function in South India. Thorax1997;52:895–899.
50.
MorganWJ. Maternal smoking and infant lung function: further evidence for an in utero effect. Am J Respir Crit Care Med1998;158:689–690.
51.
TagerIB, SegalMR, SpeizerFE, WeissST. The natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis1988;138:837–849.
52.
US Surgeon General. The health consequences of smoking: chronic obstructive pulmonary disease. Washington DC: US Department of Health and Human Services; 1984. Publication No:84-50205.
53.
LeuenbergerP, SchwartzJ, Ackermann-LiebrichU, BlaserK, BologniniG, BongardJP, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med1994;150:1222–1228.
54.
DayalHH, KhuderS, SharrarR, TrieffN.Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res1994;65:161–171.
55.
HoltPG. Immune and inflammatory function in cigarette smokers. Thorax1987;42:241–249.
56.
KauffmannF, DrouetD, LellouchJ, BrilleD.Twelve years spirometric changes among Paris area workers. Int J Epidemiol1979;8:201–212.
57.
NiewoehnerDE. Anatomic and pathophysiological correlations in COPD. In: BaumGL, CrapoJD, CelliBR, KarlinskyJB, editors. Textbook of pulmonary diseases. Philadelphia: Lippincott-Raven; 1998:823–842.
Perez-PadillaR, RegaladoU, VedalS, PareP, ChapelaR, SansoresR, et al. Exposure to biomass smoke and chronic airway disease in Mexican women. Am J Respir Crit Care Med1996;154:701–706.
60.
DossingM, KhanJ, al-RabiahF.Risk factors for chronic obstructive lung disease in Saudi Arabia. Respiratory Med1994;88:519–522.
61.
BeheraD, JindalSK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest1991;100:385–388.
62.
AmoliK.Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur Respir J1998;11:659–663.
63.
DennisR, MaldonadoD, NormanS, BaenaE, MartinezG.Woodsmoke exposure and risk for obstructive airways disease among women. Chest1996;109:115–119.
64.
PandeyMR. Prevalence of chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax1984;39:331–336.
65.
PandeyMR. Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax1984;39:337–339.
66.
SametJM, MarburyM, SpenglerJ.Health effects and sources of indoor air pollution. Am Rev Respir Dis1987;136:1486–1508.
67.
TaoX, HongCJ, YuS, ChenB, ZhuH, YangM.Priority among air pollution factors for preventing chronic obstructive pulmonary disease in Shanghai. Sci Total Environ1992;127:57–67.
68.
PrescottE, LangeP, VestboJ.Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J1999;13:1109–1114.
69.
StrachanDP. Epidemiology: a British perspective. In: CalverleyPMA, PrideNB, editors. Chronic obstructive pulmonary disease. London: Chapman & Hall; 1995:47–67.
70.
GeorgopoulasD, AnthonisenNR. Symptoms and signs of COPD. In: CherniackNS, editor. Chronic obstructive pulmonary disease. Toronto: WB Saunders; 1991:357–363.
71.
LoveridgeB, WestP, KrygerMH, AnthonisenNR. Alteration in breathing pattern with progression of chronic obstructive pulmonary disease. Am Rev Respir Dis1986;134:930–934.
72.
KestenS, ChapmanKR. Physician perceptions and management of COPD. Chest1993;104:254–258.
73.
ReisAL. Response to bronchodilators. In: ClausenJ, editor. Pulmonary function testing: guidelines and controversies. New York: Academic Press; 1982.
74.
American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis1991;144:1202–1218.
75.
WilsonDH, WakefieldMA, StevenID, RohrsheimRA, EstermanAJ, GrahamNM. "Sick of Smoking": evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust1990;152:518–521.
76.
BrittonJ, KnoxA.Helping people to stop smoking: the new smoking cessation guidelines. Thorax1999;54:1–2.
77.
FioreMC, BaileyWC, CohenSJ. Smoking cessation: information for specialists. Rockville MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and Centers for Disease Control and Prevention; 1996. AHCPR Publication No. 96-0694.
78.
The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA2000;283:244–254.
79.
American Medical Association. Guidelines for the diagnosis and treatment of nicotine dependence: how to help patients stop smoking. Washington DC: American Medical Association; 1994.
80.
GlynnTJ, ManleyMW. How to help your patients stop smoking. A National Cancer Institute manual for physicians. Bethesda MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1990. NIH Publication No. 90-3064.
81.
GlynnTJ, ManleyMW, PechacekTF. Physician-initiated smoking cessation program: the National Cancer Institute trials. Prog Clin Biol Res1990;339:11–25.
82.
FioreMC, SmithSS, JorenbyDE, BakerTB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA1994;271:1940–197.
83.
LancasterT, SteadL, SilagyC, SowdenA.Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ2000;321:355–358.
84.
The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax1997;52(Suppl 5):S1–S28.
85.
SametJ, UtellMJ. Ambient air pollution. In: RosenstockL, CullenM, editors. Textbook of occupational and environmental medicine. Philadelphia: WB Saunders; 1994:53–60.
86.
RiesAL, KaplanRM, LimbergTM, PrewittLM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med1995;122:823–832.
87.
JanelliLM, SchererYK, SchmiederLE. Can a pulmonary health teaching program alter patients' ability to cope with COPD? Rehabil Nurs1991;16:199–202.
88.
AshikagaT, VacekPM, LewisSO. Evaluation of a community-based education program for individuals with chronic obstructive pulmonary disease. J Rehabil1980;46:23–27.
89.
ToshimaMT, KaplanRM, RiesAL. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: short-term effects on exercise endurance and health status. Health Psychol1990;9:237–252.
90.
CelliBR. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med1995;152:861–864.
91.
HeffnerJE, FahyB, HillingL, BarbieriC.Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med1997;155:1055–1059.
92.
StewartMA. Effective physician-patient communication and health outcomes: a review. CMAJ1995;152:1423–1433.
93.
ClarkNM, NothwehrF, GongM, EvansD, MaimanLA, HurwitzME, et al. Physician-patient partnership in managing chronic illness. Acad Med1995;70:957–959.
94.
PauwelsRA, LofdahlCG, LaitinenLA, SchoutenJP, PostmaDS, PrideNB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med1999;340:1948–1953.
95.
VestboJ, SorensenT, LangeP, BrixA, TorreP, ViskumK.Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353:1819–1823.
96.
BurgePS, CalverleyPM, JonesPW, SpencerS, AndersonJA, MaslenTK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ2000;320:1297–1303.
97.
The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med2000;343:1902–1909.
98.
VathenenAS, BrittonJR, EbdenP, CooksonJB, WharradHJ, TattersfieldAE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis1988;138:850–855.
99.
GrossNJ, PettyTL, FriedmanM, SkorodinMS, SilversGW, Dono hueJF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study. Am Rev Respir Dis1989;139:1188–1191.
100.
ChrystynH, MulleyBA, PeakeMD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ1988;297:1506–1510.
101.
HigginsBG, PowellRM, CooperS, TattersfieldAE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J1991;4:415–420.
102.
JenkinsSC, HeatonRW, FultonTJ, MoxhamJ.Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest1987;91:804–807.
103.
IkedaA, NishimuraK, KoyamaH, TsukinoM, MishimaM, IzumiT.Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax1996;51:48–53.
104.
GuyattGH, TownsendM, PugsleySO, KellerJL, ShortHD, TaylorDW, et al. Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis1987;135:1069–1074.
105.
JonesPW, BoshTK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med1997;155:1283–1289.
106.
MahlerDA, DonohueJF, BarbeeRA, GoldmanMD, GrossNJ, WisniewskiME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest1999;115:957–965.
107.
COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest1994;105:1411–1419.
108.
COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest1997;112:1514–1521.
109.
GrossN, TashkinD, MillerR, OrenJ, ColemanW, LinbergS.Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration1998;65:354–362.
110.
UlrikCS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax1995;50:750–754.
111.
TaylorDR, BuickB, KinneyC, LowryRC, McDevittDG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis1985;131:747–751.
112.
van NoordJA, de MunckDR, BantjeTA, HopWC, AkveldML, BommerAM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J2000;15:878–885.
113.
MurcianoD, AuclairMH, ParienteR, AubierM.A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med1989;320:1521–1525.
114.
O'DriscollBR, KayEA, TaylorRJ, WeatherbyH, ChettyMC, BernsteinA.A long-term prospective assessment of home nebulizer treatment. Respir Med1992;86:317–325.
115.
TashkinDP, BleeckerE, BraunS, CampbellS, DeGraffAC Jr, HudgelDW, et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med1996;100:62S–69S.
116.
SenderovitzT, VestboJ, FrandsenJ, MaltbaekN, NorgaardM, NielsenC, et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med1999;93:715–718.
117.
RiceKL, RubinsJB, LebahnF, ParentiCM, DuanePG, KuskowskiM, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med2000;162:174–178.
118.
DecramerM, LacquetLM, FagardR, RogiersP.Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med1994;150:11–16.
119.
DecramerM, StasKJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis1992;146:800–802.
120.
NicholKL, MargolisKL, WuorenmaJ, Von SternbergT.The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med1994;331:778–784.
121.
EdwardsKM, DupontWD, WestrichMK, PlummerWD Jr, PalmerPS, WrightPF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis1994;169:68–76.
122.
SimberkoffMS, CrossAP, Al-IbrahimM, BaltchAL, GeiselerPJ, NadlerJ, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration cooperative study. N Engl J Med1986;315:1318–1327.
123.
WilliamsJH Jr, MoserKM. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med1986;104:106–109.
124.
DavisAL, ArandaCP, SchiffmanG, ChristiansonLC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease: a pilot study. Chest1987;92:204–212.
125.
IsadaCM, StollerJK. Chronic bronchitis: the role of antibiotics. In: NiedermanMS, SarosiGA, GlassrothJ, editors. Respiratory infections: a scientific basis for management. London: WB Saunders; 1994:621–633.
126.
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med1995;152:S77–S121.
127.
SiafakasNM, VermeireP, PrideNB, PaolettiP, GibsonJ, HowardP, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J1995;8:1398–1420.
128.
PoolePJ, BlackPN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev2000;2. Available from: www.update-software.com or www.updatusa.com.
129.
HansenNC, SkriverA, Brorsen-RiisL, BalslovS, EvaldT, MaltbaekN, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med1994;88:531–535.
130.
British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax1985;40:832–835.
131.
BomanG, BackerU, LarssonS, MelanderB, WahlanderL.Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis1983;64:405–415.
132.
RasmussenJB, GlennowC.Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J1988;1:351–355.
133.
ColletJP, ShapiroP, ErnstP, RenziT, DucruetT, RobinsonA.Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med1997;156:1719–1724.
134.
AnthonisenNR. OM-8BV for COPD. Am J Respir Crit Care Med1997;156:1713–1714.
135.
IrwinRS, BouletLP, CloutierMM, FullerR, GoldPM, HoffsteinV, et al. Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians. Chest1998;114:133S–181S.
136.
BarberaJA, RogerN, RocaJ, RoviraI, HigenbottamTW, Rodríguez-RoisinR.Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet1996;347:436–440.
137.
JonesAT, EvansTW. NO: COPD and beyond. Thorax1997;52(Suppl 3):S16–S21.
138.
BardsleyPA, HowardP, DeBackerW, VermeireP, MairesseM, LedentC, et al. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. Eur Respir J1991;4:308–310.
139.
WatanabeS, KannerRE, CutilloAG, MenloveRL, BachandRT Jr, SzalkowskiMB, et al. Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. Am Rev Respir Dis1989;140:1269–1273.
140.
WinkelmannBR, KullmerTH, KneisslDG, TrenkD, KronenbergerH.Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest1994;105:1383–1391.
141.
EiserN, DenmanWT, WestC, LuceP.Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. Eur Respir J1991;4:926–931.
142.
YoungIH, DaviskasE, KeenaVA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989;44:387–390.
143.
RiceKL, KronenbergRS, HedemarkLL, NiewoehnerDE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest1987;81:287–292.
144.
WoodcockAA, GrossER, GellertA, ShahS, JohnsonM, GeddesDM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med1981;305:1611–1616.
145.
PoolePJ, VealeAG, BlackPN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998;157:1877–1880.
146.
BerryMJ, RejeskiWJ, AdairNE, ZaccaroD.Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med1999;160:1248–1253.
147.
FoglioK, BianchiL, BrulettiG, BattistaL, PaganiM, AmbrosinoN.Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J1999;13:125–132.
148.
YoungP, DewseM, FergussonW, KolbeJ.Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Aust NZJ Med1999;29:59–65.
149.
GriffithsTL, BurrML, CampbellIA, Lewis-JenkinsV, MullinsJ, ShielsK, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation. a randomised controlled trial. Lancet2000;355:362–368. (Erratum appears in Lancet 2000;355:1280.)
WijkstraPJ, Van AltenaR, KraanJ, OttenV, PostmaDS, KoeterGH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J1994;7:269–273.
152.
McGavinCR, GuptaSP, LloydEL, McHardyGJ. Physical rehabilitation for the chronic bronchitic: results of a controlled trial of exercises in the home. Thorax1977;32:307–311.
153.
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med1980;93:391–398.
154.
Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet1981;1:681–686.
155.
TarpySP, CelliBR. Long-term oxygen therapy. N Engl J Med1995;333:710–714.
156.
MehranRJ, DeslauriersJ.Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am1995;5:717–734.
157.
BendittJO, AlbertRK. Surgical options for patients with advanced emphysema. Clin Chest Med1997;18:577–593.
158.
GeddesD, DaviesM, KoyamaH, HansellD, PastorinoU, PepperJ, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med2000;343:239–245.
159.
The National Emphysema Treatment Trial Research Group. Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest1999;116:1750–1761.
160.
TrulockEP. Lung transplantation. Am J Respir Crit Care Med1997;155:789–818.
161.
TheodoreJ, LewistonN.Lung transplantation comes of age. N Engl J Med1990;322:772–774.
162.
HosenpudJD, BennettLE, KeckBM, FiolB, BoucekMM, NovickRJ. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report-1998. J Heart Lung Transplant1998;17:656–668.
163.
Annual report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network. Transplant data: 1988-1994. Washington DC: Division of Transplantation, Health Resources and Services Administration, US Department of Health and Human Services; 1995.
164.
MaurerJR, FrostAE, EstenneM, HigenbottamT, GlanvilleAR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation1998;66:951–956.
165.
RegueiroCR, HamelMB, DavisRB, DesbiensN, ConnorsAF Jr, PhillipsRS. A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators. Am J Med1998;105:366–372.
166.
GibsonPG, WłodarczykJH, WilsonAJ, SprogisA.Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract1998;18:125–133.
167.
WarrenPM, FlenleyDC, MillarJS, AveryA.Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76. Lancet1980;1:467–470.
168.
AnthonisenNR, ManfredaJ, WarrenCP, HershfieldES, HardingGK, NelsonNA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med1987;106:196–204.
169.
WilsonR.The role of infection in COPD. Chest1998;113:242S–248S.
170.
SolerN, TorresA, EwigS, GonzalezJ, CelisR, El-EbiaryM, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med1998;157:1498–1505.
171.
SmithCB, KannerRE, GoldenCA, KlauberMR, RenzettiAD Jr. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis1980;141:271–280.
172.
MacFarlaneJT, ColvilleA, GuionA, MacfarlaneRM, RoseDH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet1993;341:511–514.
173.
StockleyRA, O'BrienC, PyeA, HillSL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest2000;117:1638–1645.
174.
AndersonHR, SpixC, MedinaS, SchoutenJP, CastellsagueJ, RossiG, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J1997;10:1064–1071.
175.
ChodoshS, McCartyJ, FarkasS, DrehoblM, TosielloR, ShanM, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis1998;27:722–729.
176.
WalshEE, FalseyAR, HennesseyPA. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med1999;160:791–795.
177.
MogulkocN, KarakurtS, IsalskaB, BayindirU, CelikelT, KortenV, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med1999;160:349–353.
178.
MurphyTF, SethiS, KlingmanKL, BrueggemannAB, DoernGV. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis1999;180:404–409.
179.
EmermanCL, EffronD, LukensTW. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD. Chest1991;99:595–599.
180.
EmermanCL, CydulkaRK, EffronD.Physician estimation of FEV1 in acute exacerbation of COPD. Chest1994;105:1709–1712.
181.
EmermanCL, CydulkaRK. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med1996;27:159–163.
182.
EmermanCL, ConnorsAF, LukensTW, EffronD, MayME. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med1989;18:523–527.
183.
ThompsonWH, NielsonCP, CarvalhoP, CharanNB, CrowleyJJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med1996;154:407–412.
184.
DaviesL, AngusRM, CalverleyPM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet1999;354:456–460.
185.
NiewoehnerDE, ErblandML, DeupreeRH, CollinsD, GrossNJ, LightRW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med1999;340:1941–1947.
186.
ConnorsAF Jr, DawsonNV, ThomasC, HarrellFE Jr, DesbiensN, FulkersonWJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT Investigators. Am J Respir Crit Care Med1996;154:959–967.
187.
ShepperdS, HarwoodD, GrayA, VesseyM, MorganP.Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: cost minimisation analysis. BMJ1998;316:1791–1796.
188.
GravilJH, Al-RawasOA, CottonMM, FlaniganU, IrwinA, StevensonRD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet1998;351:1853–1855.
189.
MoayyediP, CongletonJ, PageRL, PearsonSB, MuersMF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax1995;50:834–837.
190.
FernandezA, MunozJ, de la CalleB, AliaI, EzpeletaA, de la CalMA, et al. Comparison of one versus two bronchodilators in ventilated COPD patients. Intensive Care Med1994;20:199–202.
191.
BarberaJA, ReyesA, RocaJ, MontserratJM, WagnerPD, Rodríguez-RoisínR.Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. Am Rev Respir Dis1992;145:1328–1333.
192.
MahonJL, LaupacisA, HodderRV, McKirnDA, PatersonNA, WoodTE, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest1999;115:38–48.
193.
LloberesP, RamisL, MontserratJM, SerraJ, CampistolJ, PicadoC, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J1988;1:536–539.
194.
MurcianoD, AubierM, LecocquicY, ParienteR.Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med1984;311:349–353.
195.
EmermanCL, ConnorsAF, LukensTW, MayME, EffronD.Theophylline concentrations in patients with acute exacerbation of COPD. Am J Emerg Med1990;8:289–292.
196.
MeyerTJ, HillNS. Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med1994;120:760–770.
197.
International Consensus Conferences in Intensive Care Medicine. Noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med2001;163:283–291.
198.
BottJ, CarrollMP, ConwayJH, KeiltySE, WardEM, BrownAM, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet1993;341:1555–1557.
199.
BrochardL, ManceboJ, WysockiM, LofasoF, ContiG, RaussA, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med1995;333:817–822.
200.
KramerN, MeyerTJ, MehargJ, CeceRD, HillNS. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med1995;151:1799–1806.
201.
PlantPK, OwenJL, ElliottMW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet2000;355:1931–1935.
202.
EstebanA, AnzuetoA, AliaI, GordoF, ApezteguiaC, PalizasF, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med2000;161:1450–1458.
203.
EstebanA, FrutosF, TobinMJ, AliaI, SolsonaJr, ValverduI, et al. for the Spanish Lung Failure Collaborative Group. A comparison of four methods of weaning patients from mechanical ventilation. N Engl J Med1995;332:345–350.
204.
BrochardL, RaussA, BenitoS, ContiG, ManceboJ, RekikN, et al. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med1994;150:896–903.
205.
NavaS, AmbrosinoN, CliniE, PratoM, OrlandoG, VitaccaM, et al. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease: a randomized, controlled trial. Ann Intern Med1998;128:721–728.
206.
HilbertG, GrusonD, PortelL, Gbikpi-BenissanG, CardinaudJP. Noninvasive pressure support ventilation in COPD patients with postextubation hypercapnic respiratory insufficiency. Eur Respir J1998;11:1349–1353.
207.
KesslerR, FallerM, FourgautG, MennecierB, WeitzenblumE.Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med1999;159:158–164.
208.
MushlinAI, BlackER, ConnollyCA, BuonaccorsoKM, EberlySW. The necessary length of hospital stay for chronic pulmonary disease. JAMA1991;266:80–83.
209.
StollerJK, LangePA. Inpatient management of chronic obstructive pulmonary disease. Respir Care Clin N Am1998;4:425–438.
210.
PeachH, PathyMS. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax1981;36:585–589.
